Showing results (41-50 of 255) with videos related to
Sort By:
Pageof 26
Clinical and Experimental Rheumatology|March 2, 2023
Long-term survival of patients with idiopathic inflammatory myopathies: anatomy of a single-centre cohortFrancisca Guimarães, Resit Yildirim, David A IsenbergRheumatology (Oxford, England)|May 3, 2020
The assessment of patients with the antiphospholipid antibody syndrome: where are we now?Pedro Gaspar, Hannah Cohen, David A IsenbergNature Clinical Practice. Rheumatology|February 1, 2008
Conversion of discoid lupus to antiphospholipid syndrome and SLEMichelle M A Fernando, David A IsenbergExpert Opinion on Investigational Drugs|December 22, 2007
Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategyJose Maria Pego-Reigosa, David A IsenbergNature Reviews. Rheumatology|December 12, 2012
Global trends, potential mechanisms and early detection of organ damage in SLEAnselm Mak, David A Isenberg, Chak-Sing LauImmunotargets and Therapy|June 26, 2020
Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?Ana Lorenzo-Vizcaya, Serena Fasano, David A IsenbergClinical and Experimental Rheumatology|August 6, 2016
Why do patients with myositis die? A retrospective analysis of a single-centre cohortMarta Amaral Silva, Estefania Cogollo, David A IsenbergExpert Review of Clinical Pharmacology|December 29, 2015
Current pharmacological treatment of idiopathic inflammatory myopathiesSerena Fasano, Sara Custódio Alves, David A IsenbergPharmacogenomics and Personalized Medicine|February 27, 2020
Towards Precision Medicine in Systemic Lupus ErythematosusElliott Lever, Marta R Alves, David A IsenbergJournal of Immunological Methods|October 16, 2002
Optimisation of herpes simplex virus-based vectors for delivery to human peripheral blood mononuclear cellsKonstantina Papageorgiou, David A Isenberg, David S LatchmanPageof 26